

Visions for Affordable and Better Medicines

14:00 Introduction by MP Stine M. Brix from Enhedslisten, presentation of moderator Nina Le Dous and Universities Allied for Essential Medicines

14:15 Session about fair prices.

Kirsten Normann Andersen from Socialistisk Folkeparti will introduce the session asking the questions: Increasing expenses to medicine challenge our healthcare system. Why is that? What can we do about it?

The panel consists of:

The Danish Medical Council

Steen Werner Hansen, Deputy Managing Director at Herlev Hospital. Chairman of the Medicines Council and affiliated with the European Medicines Agency (EMA).

- How is the Danish system to ensure fair prices?
- Are negotiation and prioritization the best way to ensure affordable and innovative medicines?

Danish Cancer Society

Jes Søgård, professor and chief economist

- Why do medical expenses continue to rise?
- Why do the prices of hospital medicines rise?
- Problems with value based pricing

European Public Health Alliance (EPHA)

Yannis Natsis, Policy Manager for Universal Access and Affordable Medicines,

- European perspectives on the debate about affordable medicines
- How do the existing Intellectual properties system challenge affordable medicines?
- What new European initiatives exist and how is Denmark taking part in this?

Universities Allied for Essential medicines (UAEM)

Manuel Martin

- Transparency of research and development in relation to costs and prices
- How can states and society influence prices?

14:55 Video presentation from WHO: The United Nations Secretary-General's High-Level Panel on Access to Medicines Report. Promoting Innovation and Access to Health Technologies

15:00 Questions from politicians and the audience

15:20 Break with coffee

15:40 Session 2: Which incentives drive health innovation, and how do we improve them?

Pernille Schnoor from Alternativet will introduce the session asking the questions: How do we ensure innovation of medicines that benefit patients, when production is determined not by need but by profit? What alternatives do we have? Can the public, as the purchaser of medicine and research, push for research to be faster? Better suited to our health needs? Cheaper? Transparent? Easier to understand? More patient safe? More innovative?

European Public Health Alliance (EPHA)

Yannis Natsis, Policy Manager for Universal Access and Affordable Medicines

- What problems do our patent based system pose to European public health? Do we get optimal innovation, and why not?
- What initiatives exist and how is Denmark participating in these?
- How does public funded research contribute to private patents?
- Can states be better at directing research to meet public health demands (antibiotics)?

Médecins Sans Frontières/Doctors without borders (MSF)

Grania Brigden, MBChB, MRCP. TB Advisor for MSF's Access Campaign.

- How do intellectual property rules influence the work of MSF?
- A presentation of MSF's 3P campaign: <https://www.msfacecess.org/spotlight-on/3p-project-new-approach-developing-better-treatments-tb>

Leo Pharma

Tine Rikke Joergensen. Senior Director Global Public Affairs, Global Public Affairs.

- Intellectual Property rights in pharmaceutical research and development.

Universities Allied for Essential Medicines (UAEM)

Manuel Martin

- Universities role in medical research
- How we prioritize research in rare diseases or non-profitable medicines?
- Medicines Patent Pool – <https://medicinespatentpool.org/>
- Global Charter for the Advancement of Equitable Biomedical Research and Development (<http://equitablemrd.org/>)

16:35 Questions from politicians and the audience